Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis

Purpose: To provide the latest evidence on the efficacy and safety of lopinavir/ritonavir compared to other treatment options for COVID-19. Methods: We searched PubMed, Cochran Library, Embase, Scopus, and Web of Science for the relevant records up to April 2021. Moreover, we scanned MedRxiv, Google...

Full description

Bibliographic Details
Main Authors:	Bahman Amani, Ahmad Khanijahani, Behnam Amani, Payam Hashemi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31668

Similar Items

Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2020-11-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19
by: Cao, B, et al.
Published: (2020)

The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: A rapid review
by: Dorward, J, et al.
Published: (2021)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis
by: Behnam Amani, et al.
Published: (2023-12-01)

Evaluating the Effects of Umifenovir Compared to Lopinavir/Ritonavir in the Management of Patients with COVID-19: A Randomized Controlled Trial
by: Farzaneh Dastan, et al.
Published: (2022-12-01)

Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
by: Simone Meini, et al.
Published: (2020-06-01)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
by: Alexander M. Kaizer, et al.
Published: (2023-03-01)

Clinical Profiles and Il-6 Level Analysis of Critical Covid-19 Patients Receiving Lopinavir-Ritonavir
by: Erwin Astha Triyono, et al.
Published: (2023-06-01)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
by: Arabi, YM, et al.
Published: (2021)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
Published: (2013-01-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01)

Potential clinically significant life-threatening drug–drug interactions of lopinavir and ritonavir used in the treatment of COVID-19
by: Mohitosh Biswas, et al.
Published: (2020-01-01)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2020)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
by: Motahareh Amirizadeh, et al.
Published: (2023-01-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
by: German, P, et al.
Published: (2009)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
by: Byakika-Kibwika, P, et al.
Published: (2012)

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
by: Musiime, V, et al.
Published: (2014)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010)

DRUG-DRUG INTERACTIONS BETWEEN ARTEMETHER/LUMEFANTRINE AND LOPINAVIR/RITONAVIR IN HIV NEGATIVE HEALTHY VOLUNTEERS
by: German, P, et al.
Published: (2008)

Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
by: Rudin, C, et al.
Published: (2010)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021-06-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats
by: Elias Adikwu, et al.
Published: (2020-01-01)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury
by: Atousa Khalatbari, et al.
Published: (2020-06-01)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
Published: (2014-01-01)

A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities
by: Gnana Deepika Killi, et al.
Published: (2014-04-01)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022-07-01)

Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1
by: Audrey Monnin, et al.
Published: (2020-09-01)

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
by: David M Lowe, et al.
Published: (2022-10-01)

Heterogeneity of treatment effect of interferon-β1b and lopinavir–ritonavir in patients with Middle East respiratory syndrome by cytokine levels
by: Yaseen M. Arabi, et al.
Published: (2022-10-01)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
by: Gilks, C, et al.
Published: (2012)

A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease.
by: Lynne Hampson, et al.
Published: (2016-01-01)

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective
by: Anke Rotsaert, et al.
Published: (2023-03-01)

Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
by: A. B. Konkova-Reidman, et al.
Published: (2015-04-01)